



L Number	Hits	Search Text	DB	Time stamp
5	1060	544/101, 544/105	USPAT; US-PGPUB	2003/09/23 10:53
6	17727	borontrifluoride or (boron adj trifluoride)	USPAT; US-PGPUB	2003/09/23 10:49
8	69	(544/101, 544/105) and (borontrifluoride or (boron adj trifluoride))	USPAT; US-PGPUB	2003/09/23 10:52
10	330	544/101	USPAT; US-PGPUB	2003/09/23 11:34



chain nodes :

11 12 13 14 15 16 17 18 19 20 21 22 23

ring nodes :

1 2 3 4 5 6 7 8 9 10

chain bonds :

4-20 7-12 8-11 8-23 9-21 9-22 12-13 13-14 13-17 14-15 14-16 17-18 17-19

ring bonds :

1-2 1-6 1-10 2-3 3-4 4-5 5-6 6-7 7-8 8-9 9-10

exact/norm bonds :

1-10 6-7 7-8 7-12 8-9 8-11 9-10 14-15 14-16 17-18 17-19

exact bonds :

4-20 8-23 9-21 9-22 12-13 13-14 13-17

normalized bonds :

1-2 1-6 2-3 3-4 4-5 5-6

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:Atom 11:CLASS
12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS 20:CLASS
21:CLASS 22:CLASS 23:CLASS

fragments assigned reactant/reagent role:

containing 1

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 09:50:37 ON 23 SEP 2003

=> file reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.21

0.21

FILE 'REGISTRY' ENTERED AT 09:50:45 ON 23 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2003 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 22 SEP 2003 HIGHEST RN 591204-55-6

DICTIONARY FILE UPDATES: 22 SEP 2003 HIGHEST RN 591204-55-6

TSCA INFORMATION NOW CURRENT THROUGH JULY 14, 2003

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. See HELP PROPERTIES for more information. See STNote 27, Searching Properties in the CAS Registry File, for complete details:
<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=>

Uploading 10070556.str

L1 STRUCTURE UPLOADED

=> file casreact

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.40

0.61

FILE 'CASREACT' ENTERED AT 09:51:15 ON 23 SEP 2003

USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT

COPYRIGHT (C) 2003 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

FILE CONTENT:1907 - 21 Sep 2003 VOL 139 ISS 12

Some records from 1974 to 1991 are derived from the ZIC/VINITI data file and provided by InfoChem and some records are produced using some INPI

data from the period prior to 1986.

This file contains CAS Registry Numbers for easy and accurate substance identification.

Crossover limits have been increased. See HELP RNCROSSOVER for details.

Structure search limits have been raised. See HELP SLIMIT for the new, higher limits.

=> s l1

SAMPLE SEARCH INITIATED 09:51:22 FILE 'CASREACT'

SCREENING COMPLETE - 0 REACTIONS TO VERIFY FROM 0 DOCUMENTS

100.0% DONE 0 VERIFIED 0 HIT RXNS 0 DOCS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED VERIFICATIONS: 0 TO 0

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1 (0 REACTIONS)

=> s l1 sss full

FULL SEARCH INITIATED 09:51:33 FILE 'CASREACT'

SCREENING COMPLETE - 72 REACTIONS TO VERIFY FROM 13 DOCUMENTS

100.0% DONE 72 VERIFIED 22 HIT RXNS 10 DOCS


SEARCH TIME: 00.00.01

L3 10 SEA SSS FUL L1 (22 REACTIONS)

=> d fhit ibib abs tot

L3 ANSWER 1 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(8) OF 45 ...W ==> Y...




RX(8) RCT W 105939-43-9
 RGT Z 462-34-0 THF.BF3
 PRO Y 113348-94-0
 SOL 108-24-7 Ac2O
 NTE cyclization at 140.degree. for 1 h
 ACCESSION NUMBER: 137:232675 CASREACT
 TITLE: Process for preparation of optically active 2-hydroxypropoxyaniline derivatives as intermediates for levofloxacin via enzymic or microbial stereoselective hydrolysis of racemic lactic acid ester
 INVENTOR(S): Sato, Kouji, Yagi, Tsutomu; Kubota, Kazuo; Imura, Akihiro
 PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 47 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002/070726	A1	20020912	WO 2002-JP2054	20020306
W: AB, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,				

L3 ANSWER 2 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(3) OF 10 ...G ==> J...




RX(3) RCT G 105939-43-9
 RGT K 109-63-7 BF3-Et2O
 PRO J 113348-94-0
 SOL 108-24-7 Ac2O
 ACCESSION NUMBER: 134:222719 CASREACT
 TITLE: Process for the preparation of benzoxazine derivatives and intermediates therefor
 INVENTOR(S): Sato, Kouji; Takayanagi, Yoshihiro; Okano, Katsuhiko; Nakayama, Keiji; Imura, Akihiro; Itoh, Mikihiro; Yagi, Tsutomu; Kobayashi, Yukinari; Nagai, Tomoyuki
 PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan
 SOURCE: PCT Int. Appl., 139 pp.
 CODEN: PIXX02
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001/018005	A1	20010315	WO 2000-JP6094	20000907
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1211254	A1	20020605	EP 2000-957001	20000907
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
JP 2002121179	A2	20020423	JP 2000-273449	20000908
JP 2001163841	A2	20010619	JP 2000-297799	20000929
NO 2002001124	A	20020508	NO 2002-1124	20020306

Habt

L3 ANSWER 1 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)
 CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 PRIORITY APPLN. INFO.: JP 2001-63945 20010307
 OTHER SOURCE(S): MARPAT 137:232675
 GI



AB Treatment of a racemic lactate deriv. of formula MeCH(OR2)CO2R1 (R1 = C1-6 alkyl; R2 = hydroxy-protecting group) with an enzyme having an ability to hydrolyze an ester asym. causes specific hydrolysis of the ester moiety of one of the optical isomers constituting the racemic lactate deriv. to give optically active lactic acid esters (I; R1, R2 = same as above). The alkyl lactate I is reduced by metal borohydride in the presence of a primary alc. in nonalcoholic solvent to optically active 2-hydroxypropanol (II; R2 = same as above) which is condensed with trihalonitrobenzene (III; X1-X3 = halo) in the presence of a base to give 3,4-dihalo-2-(2-hydroxypropoxy)nitrobenzene deriv. (IV; R = NO2; R2, X1, X2 = same as above). Simultaneous conversion of the nitro group into the amino group and cleavage of the protecting group gives 3,4-dihalo-2-(2-hydroxypropoxy)aniline IV (R = NH2, R2 = H; X1, X2 = same as above) which is converted into levofloxacin (antibacterial) in several steps. Thus, 300 mg 2-benzoyloxypropionic acid Et ester was suspended in 0.1 M phosphate buffer (pH 6.5) and treated with 6 mg lipase (Biochem. Industry Co.) at 30.degree. for 24 h to give 102 mg (R)-2-benzoyloxypropionic acid Et ester (98.8% ee) which (100 mg) was reduced by NaBH4 in 0.15 mL MeOH and 0.8 mL toluene at 40.degree. for 3 h to give 79 mg (R)-2-benzoyloxy-1-propanol (V) (99% ee). A soln. of 4.0 g V and 4.13 g 2,3,4-trifluoronitrobenzene in 40 mL toluene was added to a suspension of 5.40 g KOH and 3.33 g K2CO3 in 180 mL toluene under ice-cooling and stirred at the same temp. for 1 h to give 7.55 g (R)-3,4-difluoro-2-(2-benzoyloxypropoxy)nitrobenzene which (1.0 g) was hydrogenated over 1.0 g 7.5% Pd/C in 10 ethanol under hydrogen atm. for 6 h to give 600 mg (R)-3,4-difluoro-2-(2-hydroxypropoxy)aniline (99.0% ee).

REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

PRIORITY APPLN. INFO.: JP 1999-253958 19990908
 JP 1999-278019 19990930
 JP 2000-239256 20000808
 JP 2000-239262 20000808
 WO 2000-JP6094 20000907

OTHER SOURCE(S): MARPAT 134:222719
 GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The invention provides an industrially advantageous process for the prepn. of antimicrobial drugs, specifically (3S)-9-halo-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (I; X = halo) (e.g. levofloxacin), and industrially advantageous processes for the prepn. of intermediates of antimicrobial drugs. The process involves, e.g. cyclization of dialkyl [(3,4-dihydro-2H-1,4-benzoxazin-4-yl)methylene]malonate deriv. (II; X1, X2 = halo; R5, R6 = C1-6 alkoxy) by treatment with Et2O.BF3 and (3S)-9,10-dihalo-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid-BF2 complex (III; X1, X2 = same as above) with 4-methylpiperazine. Thus, (2S)-2-(2,3,4-trifluoroanilino)-1-propanol, ethoxymethylenemalonate acid di-Et ester, and tetraethylammonium chloride were dissolved in acetone, treated with K2CO3, and stirred at room temp. for 4.5 h to give 84% di-Et [(2,3,4-trifluoro[15]-2-hydroxy-1-methylethyl)anilino]methylenemalonate (IV). A soln. of IV in DMF was added dropwise to potassium tert-butoxide in DMF under ice-cooling and stirred at 60.degree. for 18 h to give 79% II (X1 = X2 = F, R6 = Et) which was mixed with Ac2O, treated with Et2O.BF3 at 140.degree., and stirred at the same temp. for 1 h to give III (X1 = X2 = F). The latter compd. was dissolved in DMSO, treated with Et3N and N-methylpiperazine, stirred at room temp. for 17 h, and concd. in vacuo to dryness, and the residue was washed with Et2O, dissolved in 95% ethanol contg. Et3N, refluxed for 8 h, cooled, and evapd. in vacuo to dryness. The residue was dissolved in 5% HCl and extd. with CHCl3, and the aq. layer was adjusted at pH 11 with 1 M NaOH and then at pH 7.4 with 1 M HCl, and extd. with CHCl3 to give levofloxacin.

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT


9/23/2003

L3 ANSWER 3 OF 10 CASREACT COPYRIGHT 2003 ACS on STN


L3 ANSWER 3 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

RX(8) OF 55 ...W ==> AA...

REFERENCE COUNT: 9 THERE ARE 9 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RX(8) RCT W 106939-43-9
 PRO AA 106939-34-8
 NTE reaction run in FPE/stereoselective synthesis
 ACCESSION NUMBER: 132:22935 CASREACT
 TITLE: A practical stereoselective synthesis of
 (S)-(-)-ofloxacin
 AUTHOR(S): Yang, Yu-She; Ji, Ru-Yun; Chen, Kai-Xian
 CORPORATE SOURCE: Shanghai Institute of Materia Medica, Chinese Academy
 of Sciences, Shanghai, 200031, Peop. Rep. China
 SOURCE: Chinese Journal of Chemistry (1999), 17(5), 539-544
 CODEN: CJOCEV; ISSN: 1001-604X
 PUBLISHER: Science Press
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI



AB A very efficient and practical procedure for prepn. of (S)-(-)-ofloxacin
 (I) has been developed (10 steps, overall yield .gtoreq.45%). The key
 step of this approach is the regioselective nucleophilic substitution of
 2-position fluorine atom of 2,3,4-trifluoronitrobenzene by (S)-glycerol


L3 ANSWER 4 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

L3 ANSWER 4 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

RX(7) OF 34 ...T ==> Y...


AB The functionalization at either C-2 or C-3 of N-(tert-butoxycarbonyl)-3,4-
 difluoroaniline, based on its ortho-deprotonation under different exptl.
 conditions, is described. This process can be readily applied to the
 synthesis of ofloxacin [(+)-(-)-I], levofloxacin [(S)-I], and related
 compds.

REFERENCE COUNT: 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT



RX(7) RCT T 243448-08-0

STAGE(1)
 RGT Z 7664-93-9 H2SO4
 SOL 108-24-7 Ac2O
 STAGE(2)
 RGT H 7732-18-5 Water
 PRO Y 243448-09-1
 ACCESSION NUMBER: 131:214260 CASREACT
 TITLE: An efficient synthesis of ofloxacin and levofloxacin
 from 3,4-difluoroaniline
 AUTHOR(S): Adrio, Javier; Carretero, Juan C.; Ruano, Jose L.
 Garcia; Pallares, Antonio; Viciosa, Mercedes
 CORPORATE SOURCE: Departamento de Quimica Organica, Facultad de
 Ciencias, Universidad Autonoma de Madrid, Madrid,
 28049, Spain
 SOURCE: Heterocycles (1999), 51(7), 1563-1572
 CODEN: HETCYM; ISSN: 0385-5414
 PUBLISHER: Japan Institute of Heterocyclic Chemistry
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 GI




Habte

9/23/2003

L3 ANSWER 5 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(6) OF 48 ...R ==> U...




RX(6) RCT R 86760-99-8
RGT V 7664-93-9 H2SO4, W 108-24-7 Ac2O
PRO U 82419-34-9
NTE 50.degree.

ACCESSION NUMBER: 121:9414 CASREACT
TITLE: Process for obtaining benzoxazines useful for the synthesis of ofloxacin, levofloxacin and derivatives
INVENTOR(S): Carretero Gonzalez, Juan Carlos; Vicioso Sanchez, Mercedes; Garcia Ruano, Jose Luis
PATENT ASSIGNEE(S): Derivados del Etlico, S.A., Spain
SOURCE: PCT Int. Appl., 30 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Spanish
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9407873	A1	19940414	WO 1993-Es80	19931006
W: AT, AU, BB, BG, BR, CA, CH, CZ, DE, DK, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CP, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
ES 2055656	A1	19940816	ES 1992-1983	19921007
ES 2055656	B1	19951116		
ES 2069500	A1	19950501	ES 1993-2080	19931004
ES 2069500	B1	19960301		
EP 619311	A1	19941012	EP 1993-921930	19931006
R: AT, BE, CH, DE, DK, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07501835	T2	19950223	JP 1993-508738	19931006


L3 ANSWER 6 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(4) OF 11 ...G ==> C...



RX(4) RCT G 86760-99-8
PRO C 82419-34-9
ACCESSION NUMBER: 106:156486 CASREACT
TITLE: 9,10-Difluoro-2,3-dihydro-3-methyl-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-3-carboxylic acid and its alkyl esters
INVENTOR(S): Tanaka, Yoshiaki; Hayakawa, Isao
PATENT ASSIGNEE(S): Daiichi Seliyaku Co., Ltd., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
CODEN: JXXXXF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 6124618	A2	19861101	JP 1985-187639	19850827
JP 62057636	B4	19871202		
PRIORITY APPLN. INFO.: JP 1985-187639 19850827				
GI				




AB The title compds. [I; R = H, alkyl; R1 = F], useful as intermediates for prepn. of the antibacterial ofloxacin [(+)-I]; R = H, R1 =

Habte

L3 ANSWER 5 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

AU 674542	B2	19970102	AU 1993-51118	19931006
AU 9351118	A1	19940426		
ZA 9405098	A	19950222	ZA 1994-5098	19940713
US 5521310	A	19960528	US 1994-244455	19940831
AU 9665878	A1	19961212	AU 1996-65878	19960927
AU 686955	B2	19980212		
PRIORITY APPLN. INFO.:				ES 1992-1983 19921007
				ES 1993-2080 19931004
				WO 1993-Es80 19931006
OTHER SOURCE(S): MARPAT 121:9414				
GI				



AB The antimicrobial agents ofloxacin [(+)-I], levofloxacin [(S)-I], and their derivs. and analogs are prepd. in several steps. via (anilinomethylene)malonates II [R = H, CH₂CH(OH)R₁; R₁ = H, C1-6 alkyl (esp. Me), C2-6 alkenyl, aryl; X = halo (esp. F)] and benzoxazines III. For example, 3,4-difluoroaniline underwent N-tert-butoxycarbonylation (98-99%), lithiation and hydroxylation in the 2-position (89%), N-deprotection (86%), and condensation with di-Et (ethoxymethylene)malonate (80-81%) to give II [R = H, X = F]. Treatment of this with NaH, LiClO₄, and propylene oxide in THF gave 65% II [R = CH₂CH(OH)Me, X = F], which was cyclized by PPh₃ and di-Et azodicarboxylate (79%) to give III [R₁ = Me, X = F]. Cyclization of the latter by AcOH-H₂SO₄ (73%), sapon. by HCl-AcOH (68%), and condensation with N-methylpiperazine (79%) gave (+)-I. By using the appropriate chiral epoxide, and proceeding via enantiomeric intermediates, enantiomeric products such as (S)-I may be obtained without resolu. (claimed, no examples).


L3 ANSWER 6 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

4-methyl-1-piperaziny], were prepd., e.g., via acetylation of 2,3-difluoro-6-nitrophenol with chloroacetone, reductive intramol. cyclocondensation, condensation of the resulting difluorodihydropyridine deriv. with di-Et [(dimethylamino)methylene]malonate, intramol. cyclocondensation-decarboxylation, and optional hydrolysis of I [R = Et, R₁ = F].

9/23/2003

L3 ANSWER 7 OF 10 CASREACT COPYRIGHT 2003 ACS on STN


RX(3) OF 7 ...E ==> F

RX(3) RCT E 86760-99-8
PRO F 82419-34-9

ACCESSION NUMBER: 106:102306 CASREACT
 TITLE: Dialkyl (7,8-difluoro-2,3-dihydro-3-methyl-4H-1,4-benzoxazin-4-yl)methylene]malonates
 INVENTOR(S): Tanaka, Yoshiaki; Hayakawa, Isao
 PATENT ASSIGNEE(S): Daiichi Selyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JXOKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 61246172	A2	19861101	JP 1985-187638	19850827
JP 02004222	B4	19900126		

PRIORITY APPLN. INFO.: JP 1985-187638 19850827
GI

AB The title compds. [I; R = CH₂C(CO₂R)₂; R₁ = alkyl], useful as

L3 ANSWER 8 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(1) OF 1 A ==> B

RX(1) RCT A 86760-99-8
PRO B 82419-34-9

ACCESSION NUMBER: 102:220885 CASREACT
 TITLE: Pyridobenzoxazine derivatives
 PATENT ASSIGNEE(S): Daiichi Selyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JXOKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59216890	A2	19841206	JP 1983-88826	19830520
JP 03059904	B4	19910912		

PRIORITY APPLN. INFO.: JP 1983-88826 19830520
GI

L3 ANSWER 7 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

intermediates for the antibacterial ofloxacin, were prepd. Thus, trifluoronitrobenzene II (R₂ = F) in Me₂SO was treated with aq. KOH at 18-20.degree. for 5 h, the resulting II (R₂ = OH) refluxed with chloroacetone in acetone contg. K₂CO₃ and KI for 4 h, and the acetonoloxyl deriv. II (R₂ = OCH₂CO₂Me) was hydrogenated over Raney Ni to give, after treatment with 6N HCl, 1.HCl (R = H). This was condensed with Me₂NCH₂C(CO₂Et)₂ in HOAc at 80-90.degree. for 5 h to give 74.8% I [R = CH₂C(CO₂Et)₂].


L3 ANSWER 8 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)



AB Pyridobenzoxazine derivs. I (R = Et, H) were prepd. by treating II (R₁ = alkyl) or III (R₂, R₃ = alkyl) with acid halides and H₂SO₄. Thus, 0.5 mL 97% H₂SO₄ was added to a mixt. of 1 g II (R₁ = Et) and 2 mL AcCl at room temp. and the whole was heated for 1 h at 80-90.degree. to give 93.9% I (R = Et).

L3 ANSWER 9 OF 10 CASREACT COPYRIGHT 2003 ACS on STN

RX(1) OF 1 A ==> B




RX(1) RCT A 86760-99-8
 PRO B 82419-34-9
 ACCESSION NUMBER: 102:6509 CASREACT
 TITLE: 9,10-Difluoro-3-methyl-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid and its ethyl ester
 PATENT ASSIGNEE(S): Daiichi Selyaku Co., Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 3 pp.
 CODEN: JKKKAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 59122493	A2	19840714	JP 1982-233683	19821227
JP 02012476	B4	19900320		
PRIORITY APPLN. INFO.:			JP 1982-233683	19821227

GI


L3 ANSWER 9 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)



AB The title compds. I (R = H, Et) were prepd. by cyclocondensation of II [R1 = CH: C(CO2R2)2 (R2 = alkyl), Q (R3, R4 = alkyl)] with acid anhydrides and H2SO4. Thus, 10 mL 97% H2SO4 was added to a mixt. of 10 g II [R1 = CH: C(CO2Et)2] and 25 mL Ac2O at room temp. to give 96.3% I (R = Et).

L3 ANSWER 10 OF 10 CASREACT COPYRIGHT 2003 ACS on STN


RX(5) OF 30 ...H ==> F...



RX(5) RCT H 90785-36-7
 PRO F 90785-09-4
 ACCESSION NUMBER: 101:23460 CASREACT
 TITLE: Phenyl-substituted tricyclic antibacterial agents
 INVENTOR(S): Gerster, John F.; Stern, Richard M.
 PATENT ASSIGNEE(S): Riker Laboratories, Inc., USA
 SOURCE: U.S., 11 pp.
 CODEN: USXQAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4443447	A	19840417	US 1982-436376	19821025
EP 107201	A2	19840502	EP 1983-110613	19831024
EP 107201	A3	19840822		
R: DE, FR, GB				
JP 59095285	A2	19840601	JP 1983-198968	19831024
US 4603199	A	19860729	US 1984-574045	19840126
PRIORITY APPLN. INFO.:			US 1982-436376	19821025

GI



Habte

L3 ANSWER 10 OF 10 CASREACT COPYRIGHT 2003 ACS on STN (Continued)

AB The antibacterial (no data) tricyclic compds. I (X = O, CH2, NMe; m = 0, 1; R = H, O2N, H2N, alkyl, alkanamido, dialkylamino, HCONH, HO, alkoxy, haloalkanamido, pyrrol, n = 1, 2; R1 = H, Me, F, Cl, O2N) and their derivs. were prepd. Thus, 2,6-(O2N)PhC6H3OCH2COMe underwent reductive cyclization to give 3,4-dihydro-5-phenyl-2H-1,4-benzoxazine, which was condensed with EtOCH: C(CO2Et)2 followed by cyclization with polyphosphoric acid and hydrolysis to give the pyridobenzoxazine II.

9/23/2003

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

140.05

140.66

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-6.20

-6.20

STN INTERNATIONAL LOGOFF AT 09:52:01 ON 23 SEP 2003